IMMUNOGENIC MEDICINAL FORMULATION FOR PHARMACEUTICAL USE, CONTAINING RECOMBINANT LIVE BCG THAT EXPRESS ANTIGENS OF METAPNEUMOVIRUS (HMPV), IN SUSPENSION PREPARED FROM LYOPHILISATE, WITHOUT ADDITION OF ADJUVANT Russian patent published in 2018 - IPC A61K39/155 A61K39/04 A61P31/14 C12N15/45 

FIELD: biotechnology.

SUBSTANCE: disclosed is an immunogenic formulation providing protection against HMPV of subtype A and/or attenuating the pathogenicity caused by HMPV of subtype A, and containing one or more recombinant attenuated strains of mycobacterium obtained from the strain of Calmette-Guerin bacillus (BCG) in an amount of 10⁴ to 10⁹ bacteria (CFU / dose) per strain, and in which each strain expresses the P-protein, which is the P-protein of HMPV, in a pharmacologically appropriate salt buffer. Disclosed is a method of protecting against HMPV infection or a disease caused by HMPV, comprising administering to said patient an immunogenic formulation.

EFFECT: group of inventions provides effective protection against HPMV without causing inflammatory hypersensitivity.

8 cl, 6 dwg, 6 ex